「Reata pharmaceuticals inc investor relations」熱門搜尋資訊

Reata pharmaceuticals inc investor relations

「Reata pharmaceuticals inc investor relations」文章包含有:「BiogentoAcquireReataPharmaceuticals」、「DEFA14A」、「ReataPharmaceuticals」、「ReataPharmaceuticals(RETA)InvestorRelationsMaterial」、「ReataPharmaceuticals2023AnnualMeeting」、「ReataPharmaceuticals」、「ReataPharmaceuticals」、「ReataPharmaceuticals」

查看更多
Reata Pharmaceuticals
Provide From Google
Biogen to Acquire Reata Pharmaceuticals
Biogen to Acquire Reata Pharmaceuticals

https://investors.biogen.com

Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.

Provide From Google
DEFA14A
DEFA14A

https://www.sec.gov

On July 28, 2023, Biogen Inc. (the “Company”) and Reata Pharmaceuticals, Inc. (“Reata”) issued a joint press release announcing the entry ...

Provide From Google
Reata Pharmaceuticals
Reata Pharmaceuticals

https://www.biogen.com

Reata Pharmaceuticals has been acquired by Biogen.

Provide From Google
Reata Pharmaceuticals (RETA) Investor Relations Material
Reata Pharmaceuticals (RETA) Investor Relations Material

https://quartr.com

Access Reata Pharmaceuticals Inc (RETA) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using Quartr.

Provide From Google
Reata Pharmaceuticals 2023 Annual Meeting
Reata Pharmaceuticals 2023 Annual Meeting

https://www.proxydocs.com

Annual Meeting. The annual meeting of Reata Pharmaceuticals will be held on Wednesday, June 7, 2023, at 8:00 AM Central Time. The meeting will only be held ...

Provide From Google
Reata Pharmaceuticals
Reata Pharmaceuticals

https://www.annualreports.co.u

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases.

Provide From Google
Reata Pharmaceuticals
Reata Pharmaceuticals

https://www.annualreports.com

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases.

Provide From Google
Reata Pharmaceuticals
Reata Pharmaceuticals

https://www.businesswire.com

Reata Pharmaceuticals, Inc. (972) 865-2219 https://www.reatapharma.com/. Investor Relations & Media Relations: John Hunter [email protected]